{
  "paper_metadata": {
    "pmid": "38036573",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the BRCA2 variant 999del5, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.771_775delTCAAA",
      "protein_notation": "p.Asn257LysfsTer17",
      "genomic_position": "rs80359671",
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 160,
        "demographics": "Women diagnosed with breast cancer in Iceland from 1980-2004",
        "phenotype": "Breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 160,
        "affected_count": 72,
        "unaffected_count": 88,
        "uncertain_count": null,
        "penetrance_percentage": 45.0,
        "age_dependent_penetrance": [
          {
            "age_range": "\u226440 years",
            "penetrance_percentage": 55.2,
            "carriers_in_range": 33,
            "affected_in_range": 18
          },
          {
            "age_range": ">40 years",
            "penetrance_percentage": 27.0,
            "carriers_in_range": 127,
            "affected_in_range": 54
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": 47,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "Breast cancer",
          "evidence_sentence": "Deaths, no. (% of all cases) 114 (71.3) among BRCA2 carriers."
        },
        {
          "individual_id": "Case_2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": 36,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "Breast cancer, diagnosed at a young age",
          "evidence_sentence": "Young cases had the lowest proportion of ER+ tumors (60.7%) but the highest proportion of HER2-positive tumors (27.9%)."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 999del5 variant is associated with increased risk of breast cancer.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families, as indicated by the higher prevalence among breast cancer patients.",
      "population_frequency": "0.8% in the general population, 7-8% among breast cancer patients in Iceland.",
      "evidence_level": "Strong evidence based on population studies and clinical outcomes.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variant is a founder mutation in the Icelandic population.",
      "key_quotes": [
        "The prevalence of the BRCA2 mutation among tested patients <=40 years of age was 21.0%, but it was 5.4% among women diagnosed >40 years of age.",
        "For ER+ cancer, breast cancer-specific 15-year survival was 49.7% among BRCA2-carriers."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Clinical characteristics and treatment of patients.",
      "variants_extracted": 1
    },
    {
      "table_name": "Table 2",
      "table_caption": "BRCA2 carriers and young non-carrier patients compared with older non-carrier patients stratified by ER status.",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Data was extracted thoroughly from both the main text and tables."
  }
}